In contrast, excepting a small fraction of ERBC with high mutation load, immune infiltration and improved survival (15), very few studies have documented significant CD8+ T cell infiltration in most ERBC which comprise more than two thirds of all newly diagnosed breast cancers. The gene discussed is CD8A; the disease is breast carcinoma.